(Q36108621)

12 August 2017

1 reference

title

Small molecule and monoclonal antibody therapies in neurooncology (English)

1 reference

12 August 2017

1 reference

Nicholas Butowski

1

1 reference

12 August 2017

Susan M Chang

series ordinal

2

1 reference

12 August 2017

language of work or name

1 reference

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

12

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

116-124

1 reference

An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Brain and other central nervous system tumors: rates, trends, and epidemiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Development of novel targeted therapies in the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Emerging molecular therapies for brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Using mice to decipher the molecular genetics of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Platelet-derived growth factor in human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Recent advances in the molecular genetics of primary gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Monoclonal antibody therapy of human gliomas: current status and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

The EGFR as a target for anticancer therapy--focus on cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Coordinate regulation of translation by the PI 3-kinase and mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Wortmannin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Clinical development of mammalian target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Aberrant G protein signaling in nervous system tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Proliferation of human malignant astrocytomas is dependent on Ras activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Angiogenic factors in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Mechanisms of angiogenesis in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Advances in Molecular Therapies in Patients with Brain Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480501200207

10.1177/107327480501200207

21 January 2018

Identifiers

DOI

0 references

1 reference